5-溴脫氧尿嘧啶核苷作用機(jī)制 - Medchemexpress - MCE中國(guó)

1、Product Data Sheet5-BrdUCat. No.: HY-15910CAS No.: 59-14-3分式: CHBrNO分量: 307.1作靶點(diǎn): Nucleoside Antimetabolite/Analog作通路: Cell Cycle/DNA Damage儲(chǔ)存式: 4C, protect from light* In solvent : -80C, 6 months; -20C, 1 month (protect from light)溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 41 mg/mL (133.51 mM)H2O : 33.33 mg/mL (108.53 mM; N

2、eed ultrasonic)* means soluble, but saturation unknown.SolventMass1 mg 5 mg 10 mgConcentration制備儲(chǔ)備液1 mM 3.2563 mL 16.2813 mL 32.5627 mL5 mM 0.6513 mL 3.2563 mL 6.5125 mL10 mM 0.3256 mL 1.6281 mL 3.2563 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存式和期限：-80C, 6 months; -20C, 1 month (

3、protect from light)。-80C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?6 個(gè)內(nèi)使，-20C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?1 個(gè)內(nèi)使。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?。以下溶解案都?qǐng)先按照 In Vitro 式配制澄清的儲(chǔ)備液，再依次添加助溶劑：為保證實(shí)驗(yàn)結(jié)果的可靠性，澄 的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使； 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的式助溶1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility:

4、2.08 mg/mL (6.77 mM); Clear solution此案可獲得 2.08 mg/mL (6.77 mM，飽和度未知) 的澄清溶液。以 1 mL 作液為例，取 100 L 20.8 mg/mL 的澄 DMSO 儲(chǔ)備液加到 400 L PEG300 中，混合均勻；向上述體系中加50 L Tween-80，混合均勻；然后繼續(xù)加 450 L 理鹽定容 1 mL。2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.08 mg/mL (6.77 mM); Clear solution此案可獲得 2.08 mg/m

5、L (6.77 mM，飽和度未知) 的澄清溶液。Page 1 of 2 www.MedChemE以 1 mL 作液為例，取 100 L 20.8 mg/mL 的澄均勻。DMSO 儲(chǔ)備液加到 900 L 20% 的 SBE-CD 理鹽溶液中，混合3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.08 mg/mL (6.77 mM); Clear solution此案可獲得 2.08 mg/mL (6.77 mM，飽和度未知) 的澄 溶液，此案不適于實(shí)驗(yàn)周 期在半個(gè)以上的實(shí)驗(yàn)。以 1 mL 作液為例，取 100 L 20.8 mg/mL 的澄 DMS

6、O 儲(chǔ)備液加到 900 L 油中，混合均勻。BIOLOGICAL ACTIVITY物活性 5-BrdU種核苷類似物，可與胸苷競(jìng)爭(zhēng)摻DNA。5-BrdU通常于檢測(cè)增殖細(xì)胞。體外研究 Bromodeoxyuridine induces a progressive, dose-responsive suppression of cancer cell line and cancer stem cellpopulation expansion RG2 rat glioma cells. In H9 cells and BJ fibroblasts, bromodeoxyuridine alters t

7、he cell cycleprofile1. BrdU is stably integrated into the DNA, and thus can be used in assessment of cell proliferation and othercell procession2.體內(nèi)研究 Bromodeoxyuridine (300 mg/kg, i.p. or 0.8 mg/mL, p.o.) significantly slows tumor progression in rat glioma RG2tumor model1.PROTOCOLCell Assay 1 Cultu

8、res are initially plated at 2000 cells/cm2 and are quantified with a Z2 Coulter Counter. RG2 rat glioma cells aretreated once with 0, 1, 10, or 50 M BrdU for 24 hours, and cumulative growth curves are obtained over 18 days.Control and treated cells are quantified and replated at equal densities on d

9、ays 5, 12, and 18 after treatment.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Cell Res. 2020 Apr 30. Cell Res. 2019 Jan;29(1):23-41. EBioMedicine. 2018 Dec. J Mol Cell Cardiol. 2018 May;118:133-146. J Mol Med (Berl). 2019 Aug;97(8):1183-

10、1193.See more customer validations on HYPERLINK www.MedChemE www.MedChemEREFERENCES1. Levkoff LH, et al. Bromodeoxyuridine inhibits cancer cell proliferation in vitro and in vivo. Neoplasia. 2008 Aug;10(8):804-16.2. Rothaeusler K, et al. Assessment of cell proliferation by 5-bromodeoxyuridine (BrdU) labeling for multicolor flow cytometry. Curr Protoc Cytom. 2007Apr;Chapter 7:Unit7.31Page 2 of 3 www.MedChemEMcePdfHeightCaution: Product has not been fully validated for medi